BioCentury
ARTICLE | Company News

Merck & Co., Institute for Research in Immunology and Cancer-Commercialization of Research (IRICoR) cancer, autoimmune news

April 29, 2013 7:00 AM UTC

Merck will provide C$4 million ($3.9 million) in funding to IRICoR to identify, develop and commercialize healthcare technologies in collaboration with MaRs Innovation (Toronto, Ontario) and the Centre for Drug Research and Development (Vancouver, B.C.). IRICoR is a not-for-profit dedicated to commercializing cancer, immunology and other drugs discovered by the Universite de Montreal, while MaRs is the commercialization agent for 16 Ontario academic institutions. The Centre for Drug Research and Development is a not-for-profit, which aims to translate publicly funded research into the private sector. ...